Human Papillomavirus Genotypes in Anal High-Grade Squamous Intraepithelial Lesion (HSIL): Anal Intraepithelial Neoplasia Grades 2 (AIN2) and 3 (AIN3) Are Different
Jennifer M Roberts, Isobel M Poynten, Monica Molano, Dorothy A Machalek, Richard J Hillman, Patricia Guzman, Fengyi Jin, David J Templeton, Christopher K Fairley, Carmella Law, Suzanne M Garland, Andrew E Grulich, Alyssa M Cornall
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | AMER ASSOC CANCER RESEARCH | Published : 2020
BACKGROUND: Anal high-grade squamous intraepithelial lesion (HSIL) can be histomorphologically categorized into anal intraepithelial neoplasia (AIN) grade 2 (AIN2) and grade 3 (AIN3). Different risk factors for these two categories have been described. We investigated whether there were also differences in lesion-specific human papillomavirus (HPV) genotypes. METHODS: The Study of the Prevention of Anal Cancer (SPANC) recruited 617 gay and bisexual men (GBM); 36% of participants were HIV positive. At baseline, 196 men (31.8%) had histologic HSIL lesions. Tissue was available for genotyping in 171, with a total of 239 HSIL lesions (183 AIN3 and 56 AIN2). Using laser capture microdissection, e..View full abstract
Awarded by National Health and Medical Research Council Program Grant (Sexually Transmitted Infections: causes, consequences, and interventions)
Awarded by Cancer Council New South Wales Strategic Research Partnership Program Grant (Preventing morbidity and mortality from anal cancer)
Awarded by Cancer Council Victoria
The authors would like to acknowledge Brian Acraman, Marjorie Adams, Clare Biro, Andrew Carr, Susan Carroll, Simon Comben, Craig Cooper, Leonie Crampton, Erin Cvejic, Deborah Ekman, Jeanne Ellard, Amber Ellis, Lance Feeney, Marko Garcia, Sian Goddard, Kirsten Howard, Patrick Kelly, Matthew Law, Kirsten McCaffery, Ross McDonald, Patrick McGrath, Alan Meagher, Robert Mellor, Matthew O'Dwyer, Kathy Petoumenos, Piero Pezzopane, Garrett Prestage, Adele Richards, Daniel Seeds, Nicola Sharp, Julia Thurloe, Winnie Tong, Rick Varma, and St Vincent's Centre for AppliedMedical Research Clinical Trials & Biorepository Team for their contribution to the study. This work was supported by National Health and Medical Research Council Program Grant (Sexually Transmitted Infections: causes, consequences, and interventions; grant no. 568971; to A.E. Grulich), Cancer Council New South Wales Strategic Research Partnership Program Grant (Preventing morbidity and mortality from anal cancer; grant no. 13-11; to A.E. Grulich, I.M. Poynten, to F. Jin), and Cancer Council Victoria grant for evaluating molecular biomarkers of anal cancer risk (application no. APP1130507; to S.M. Garland, M. Molano, A.M. Cornall). The Kirby Institute is affiliated with the Faculty of Medicine, University of New South Wales and funded by the Australian Government of Health and Ageing. Cytologic testing materials were provided by Hologic (Australia) Pty Ltd.